Actively Recruiting
Study of Oral Tributyrin to Prevent Radiation-Induced Rectal Injury During Chemoradiotherapy for Locally Advanced Rectal Cancer
Led by Sixth Affiliated Hospital, Sun Yat-sen University · Updated on 2026-09-03
23
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of tributyrin, a dietary supplement, to prevent acute radiation-induced rectal injury ARII in people with locally advanced rectal cancer undergoing standard neoadjuvant chemoradiotherapy. This prospective, single-arm trial aims to assess the safety and potential benefits of adding tributyrin to regular cancer treatment. The study will focus on whether tributyrin reduces the occurrence of moderate to severe ARII as classified by medical criteria. Participants will take oral tributyrin at a dose of 1,650 mg three times daily after meals, starting on the first day of radiotherapy and continuing until 28 days after finishing short-course radiotherapy or 14 days after long-course radiotherapy. In addition to tributyrin, participants will receive standard pelvic radiotherapy and standard clinical care, which includes dietary advice, symptom management, probiotics, medications for diarrhea and nausea, oral rehydration, and skin-care products. Extra treatments may be given if significant side effects occur. During the study, participants will be monitored from the start of radiotherapy until three months after its completion to measure the incidence of moderate or worse acute radiation-induced rectal injury. The team will also assess longer-term chronic rectal injury up to 12 months after radiotherapy. Health-related quality of life and bowel function will be evaluated using questionnaires. Safety assessments will track treatment-related adverse events throughout the study period. Total participation spans from the initiation of radiotherapy through follow-up assessments up to one year.
CONDITIONS
Brief Title
A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer
Research Team
L
Lekun Fang
W
Weiyao Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here